We are live on ! Find out more
XENT

Intersect ENT, Inc

Delisted

XENT was delisted on the 12th of May, 2022.

108 hedge funds and large institutions have $611M invested in Intersect ENT, Inc in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more call options, than puts

Call options by funds: $6.7M | Put options by funds: $6.43M

2% less funds holding

Funds holding: 110108 (-2)

8% less capital invested

Capital invested by funds: $661M → $611M (-$49.7M)

10% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 39

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
108
Holders Change
-2
Holders Change %
-1.82%
% of All Funds
1.9%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
35
Reduced
39
Closed
15
Calls
$6.7M
Puts
$6.43M
Net Calls
+$274K
Net Calls Change
-$1.68M
Name Holding Trade Value Shares
Change
Change in
Stake
Artisan Partners
1
Artisan Partners
Wisconsin
$78.7M +$18.5M +801,723 +27%
BlackRock
2
BlackRock
New York
$62.1M +$2.06M +89,386 +3%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$57.6M -$4.65M -201,649 -7%
FLAM
4
First Light Asset Management
Minnesota
$42.5M +$18.8M +813,684 +67%
Vanguard Group
5
Vanguard Group
Pennsylvania
$35.6M +$882K +38,222 +2%
GPP
6
Great Point Partners
Connecticut
$27.8M +$690K +29,902 +2%
RSCM
7
Rock Springs Capital Management
Maryland
$22.6M +$8.77M +380,200 +54%
Neuberger Berman Group
8
Neuberger Berman Group
New York
$20.5M -$1.26M -54,804 -5%
State Street
9
State Street
Massachusetts
$19.6M +$1.32M +57,251 +7%
Jennison Associates
10
Jennison Associates
New York
$19.1M -$2.93M -126,953 -12%
PVI
11
Pura Vida Investments
New York
$19M +$1.24M +53,937 +6%
Citadel Advisors
12
Citadel Advisors
Florida
$14.9M -$6.29M -272,382 -28%
N
13
Nuveen
North Carolina
$13.8M -$687K -29,751 -4%
BG
14
Bellevue Group
Switzerland
$12.9M -$34.9K -1,513 -0.2%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$11.2M +$846K +36,679 +7%
NHAS
16
Novo Holdings A/S
Denmark
$10.6M +$155K +6,697 +1%
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$10.4M +$321K +13,897 +3%
Northern Trust
18
Northern Trust
Illinois
$8.02M -$799K -34,641 -8%
UBS Group
19
UBS Group
Switzerland
$7.53M -$21.7M -939,765 -72%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$7.31M -$2.21M -95,793 -21%
SAM
21
Silvercrest Asset Management
New York
$6.51M +$7.19M +311,601 New
Balyasny Asset Management
22
Balyasny Asset Management
Illinois
$6.27M -$2.36M -102,224 -25%
JP Morgan Chase
23
JP Morgan Chase
New York
$5.92M -$1.34M -57,970 -17%
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$5.73M +$275K +11,902 +5%
GLA
25
Great Lakes Advisors
Illinois
$5.51M +$321K +13,928 +6%

XENT Hedge Fund Activity: Q1 2021 in Review

108 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q1 2021, worth a combined $611M — down 7.5% from $661M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of XENT and 13 opened new positions — a net loss of 2 holders — while 39 trimmed existing stakes and 35 added.

The largest buyer was First Light Asset Management, adding an estimated $18.8M. The largest seller was UBS Group, cutting an estimated $21.7M.

  • 108 institutional investors held Intersect ENT, Inc (XENT) as of Q1 2021, down from 110 in Q4 2020.
  • Funds reported $611M of Intersect ENT, Inc stock for Q1 2021, down 7.5% quarter-over-quarter.
  • 13 funds opened new Intersect ENT, Inc positions in Q1 2021 and 15 closed out, a net change of -2 holders.
  • The largest Intersect ENT, Inc buyer in Q1 2021 was First Light Asset Management, an estimated $18.8M added.
  • The largest Intersect ENT, Inc seller in Q1 2021 was UBS Group, an estimated $21.7M sold.

Based on aggregated 13F filings for Q1 2021.